Medical Editor: John P. Cunha, DO, FACOEP
Timentin (ticarcillin disodium and clavulanate potassium) for Injection is a combination of antibiotics used to treat many different infections caused by bacteria, such as urinary tract infections, bone and joint infections, severe vaginal infections, stomach infections, and skin infections. Common side effects of Timentin Injection include:
- stomach pain
- joint or muscle pain
- skin rash or itching
- injection site reactions (pain, swelling, or burning), or
- vaginal yeast infection (itching or discharge)
The usual recommended dosage for systemic and urinary tract infections for adults is 3.1 grams of Timentin given every 4 to 6 hours. For moderate gynecologic infections, the dose is 200 mg/kg/day in divided doses every 6 hours; Severe infections, 300 mg/kg/day in divided doses every 4 hours. Timentin may interact with other drugs. Tell your doctor all medications and supplements you use. Timentin is not expected to be harmful to a fetus. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Timentin can make birth control pills less effective. Use a second non-hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using this drug. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Our Timentin (ticarcillin disodium and clavulanate potassium) for Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following are discussed in more detail in other sections of the labeling:
- Anaphylactic Reactions [see WARNINGS AND PRECAUTIONS]
- Clostridium difficile Associated Diarrhea [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions occurring in ≥ 1% of 867 patients receiving TIMENTIN 3.1 grams in clinical studies included rash, nausea, diarrhea, and phlebitis at the injection site. The most common laboratory abnormalities ( ≥ 3%) were elevations in eosinophils, serum aspartate aminotransferase (AST), and serum alanine aminotransferase (ALT).
Available safety data for pediatric patients treated with TIMENTIN demonstrate a similar adverse event profile to that observed in adult patients.
In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use of TIMENTIN. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These adverse reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to TIMENTIN.
Skin rash, pruritus, urticaria, arthralgia, myalgia, drug fever, chills, chest discomfort, anaphylactic reactions, and bullous reactions (including erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome).
Central Nervous System
Headache, giddiness, neuromuscular hyperirritability, or convulsive seizures.
Disturbances of taste and smell, stomatitis, flatulence, nausea, vomiting and diarrhea, epigastric pain, and pseudomembranous colitis have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see WARNINGS AND PRECAUTIONS].
Hemic and Lymphatic Systems
Abnormalities of Hepatic Function Tests
Elevation of AST, ALT, serum alkaline phosphatase, serum LDH, and serum bilirubin. There have been reports of transient hepatitis and cholestatic jaundice, as with some other penicillins and some cephalosporins.
Renal and Urinary Effects
Read the entire FDA prescribing information for Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
© Timentin Injection Patient Information is supplied by Cerner Multum, Inc. and Timentin Injection Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.